Cboe CA - Delayed Quote CAD
Gilead Sciences, Inc. (GILD.NE)
21.61
+0.06
+(0.28%)
At close: May 2 at 2:43:12 PM EDT
Research Analysis
Earnings Estimate
| Currency in USD | Current Qtr. (Jun 2025) | Next Qtr. (Sep 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| No. of Analysts | -- | -- | -- | -- |
| Avg. Estimate | 0 | 0 | 0 | 0 |
| Low Estimate | 0 | 0 | 0 | 0 |
| High Estimate | 0 | 0 | 0 | 0 |
| Year Ago EPS | -- | -- | -- | -- |
Revenue Estimate
| Currency in USD | Current Qtr. (Jun 2025) | Next Qtr. (Sep 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| No. of Analysts | 19 | 18 | 27 | 28 |
| Avg. Estimate | 6.95B | 7.39B | 28.65B | 29.71B |
| Low Estimate | 6.74B | 7.2B | 28.28B | 28.7B |
| High Estimate | 7.27B | 7.58B | 29.45B | 31.88B |
| Year Ago Sales | 6.95B | 7.54B | 28.75B | 28.65B |
| Sales Growth (year/est) | -0.00% | -2.10% | -0.36% | 3.68% |
EPS Trend
| Currency in USD | Current Qtr. (Jun 2025) | Next Qtr. (Sep 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| Current Estimate | 0 | 0 | 0 | 0 |
| 7 Days Ago | 0 | 0 | 0 | 0 |
| 30 Days Ago | 0 | 0 | 0 | 0 |
| 60 Days Ago | 0 | 0 | 0 | 0 |
| 90 Days Ago | 0 | 0 | 0 | 0 |
EPS Revisions
| Currency in USD | Current Qtr. (Jun 2025) | Next Qtr. (Sep 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | -- | -- | -- | -- |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| Current Qtr. | Next Qtr. | Current Year | Next Year | |
|---|---|---|---|---|
| GILD.NE | -- | -- | -- | -- |
| S&P 500 | 12.47% | 3.19% | 8.01% | 13.87% |
Related Tickers
AMGN.NE AMGEN CDR (CAD HEDGED)
21.18
-3.38%
ROG.NE Roche Holding AG
21.31
+0.47%
MRK.NE Merck & Co., Inc.
19.13
+0.10%
NVON.NE NOVO NORDISK CDR (CAD HEDGED)
7.41
+3.64%
LLY.NE Eli Lilly and Company
30.45
+3.85%
AMGN Amgen Inc.
281.22
-0.90%
OGN Organon & Co.
9.59
+1.48%
JNJ Johnson & Johnson
156.12
+1.07%
NVO Novo Nordisk A/S
69.23
+5.53%
ABBV AbbVie Inc.
198.47
+2.65%